Early trial explores HBM1020 for Hard-to-Treat cancers
NCT ID NCT05824663
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This early-phase study tested a new drug called HBM1020 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. The study did not aim to cure the cancer, but to see if the drug could help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Denver Health
Denver, Colorado, 80204, United States
Conditions
Explore the condition pages connected to this study.